News

A draft ICER report found that baxdrostat and lorundrostat don't lower blood pressure more than older generics but do cost much more.

The REAL Health Providers Act and the CMS National Provider Directory (NPD) initiative will to reshape how provider data is collected, maintained, and enforced.

Healthcare journalist Ken Terry’s new book proposes a subscription-based primary care system as a free-market alternative to Medicare for All.

Will Carroll, Pharm.D., chief pharmacy officer at Sutter Health, discusses strategic priorities and his vision for specialty pharmacy growth.

Perry Cohen, Pharm.D., speaks with Dipak Patel, CEO of Globo, about communication in healthcare, particuarly translation services.

Joseph Savasta, founder and CEO of pharmacy benefit manager HarmonyRx, discusses why the company keeps rejecting acquisition offers amid PBM consolidation.

Patel, senior vice president of trade relations and supply chain at MedImpact, discusses his career path and current responsibilities. at MedImpact.

In this discussion, Brian Coffman, Ph.D., Director of the Clinical Neurophysiology Research Laboratory at the UPMC Western Psychiatric Hospital and Director of Research at UPMC Brain Mapping Center, explores how cannabis-associated psychosis may differ biologically from schizophrenia and what these insights mean for patients and clinicians.

Robyn S. Crosson, J.D., VP of government relations at Navitus Health Solutions, has won the PBMI Innovators Award for her work advancing transparency in pharmacy benefits.

A survey with just over 400 employer respondents showed a declining percentage use one of three large pharmacy benefit managers (PBMs) to manage their drug benefits and coverage.

Novo Nordisk’s ziltivekimab lowers IL-6 heart inflammation but misses MACE reduction in ZEUS phase 3 CVD trial, with higher serious infections risk.

Raechele McMahan of Prescryptive Health says a cancer diagnosis at 17 and her son's type 1 diabetes made health care access personal before professional.

CMS has finalized a rule cutting federal Medicaid and CHIP funding for gender-affirming care for minors, effective Oct. 13, 2026.

Lower levels of the protein IQGAP2 were linked to more aggressive esophageal squamous cell carcinoma and worse survival.

Patrick Gleason, Pharm.D., of Prime Therapeutics was named a 2026 PBMI Innovator for his work on cost-effective formulary strategy and real-world evidence generation.

Online drug platforms are expanding quickly, but lower sticker prices do not always mean lower total costs for employees or better coordination of care.

Robyn S. Crosson, J.D., of Navitus Health Solutions, Elizabeth Mitchell of Purchaser Business Group on Health and Kathy W. Oubre, M.S., of the Pontchartrain Cancer Center, discussed PBM reform and transparency during an MHE webinar today.

Under CMS's new Medicaid work rule, a qualifying medical condition alone won't exempt enrollees. They must also show impairment in a daily living activity.

Awiqli is the first once-weekly basal insulin for Type 2 diabetes. It has a list price of $99 a package and is also available for a $35 copay for eligible patients.

In this discussion, Hanna Gustafsson, Ph.D. and Elinor Sullivan, Ph.D., who are researchers from Oregon Health & Science University’s Center for Mental Health Innovation, explain the potential relationship between early childhood caregiving and ADHD.

Post-op oral dexamethasone after pediatric tonsillectomy reduces tonsillectomy pain and sharply lowers opioid prescribing and ED visits, a randomized trial finds.

The phase 3 trial will evaluate the efficacy of pemvidutide, a dual glucagon/GLP-1 receptor agonist, in metabolic dysfunction-associated steatohepatitis patients with moderate to advanced fibrosis, using an AI tool to standardize liver biopsy assessment.

David Chen, Pharm.D., of Kaiser Permanente discusses how PBM reform could speed biosimilar adoption and lower drug costs.

The real challenge for health plans isn’t simply deciding how to automate prior authorization but using this regulatory moment to build a far more durable cost-management strategy.

Phase 3 trials showed improvements in daytime wakefulness, cataplexy, and the disorder's full symptom range, including sleep paralysis and hallucinations.

New research in Menopause shows diabetic women face greater symptom burden during menopause transition, suggesting diabetes care should incorporate menopause symptom assessment and management.

Epic Research finds 2026 cholesterol guidelines and PREVENT-ASCVD expand statin eligibility to 54.6%, reshaping hyperlipidemia prevention and cardiovascular diseases risk.

Eric Levine, M.P.H., principal at Avalere Health, explains why a diagnosis alone won't exempt someone from the Medicaid work requirements that go into effect in 2027.